Biochemical Assay Services for Alzheimer’s Disease R&D
At Ace Therapeutics, we provide robust biochemical profiling services to advance your Alzheimer's disease (AD) drug discovery pipeline. Our assays focus on the molecular drivers of AD pathology—amyloid-beta (Aβ) aggregation, tau hyperphosphorylation, and enzymatic dysregulation—delivering precise, reproducible data to guide compound optimization and mechanistic validation.
Alzheimer's disease is characterized by complex biochemical disruptions, from misfolded protein accumulation to impaired proteolytic processing. Traditional cell-based or in vivo models often lack the resolution to dissect these mechanisms at the molecular level. Our biochemical assays address this gap by
Evaluate compounds targeting Aβ pathology.
Characterize compounds modulating tau pathology.
Assess inhibitors or modulators of AD-relevant enzymes.
Validate AD biomarkers in preclinical models.
At Ace Therapeutics, we leverage advanced biochemical tools to dissect Alzheimer's pathology at the molecular level—whether tracking amyloid-beta aggregation kinetics, resolving tau phosphorylation dynamics, or quantifying enzymatic dysregulation. Our technologies are designed to deliver high-resolution, reproducible data, empowering you to refine drug candidates with precision while minimizing off-target risks.
| Technology | Application |
| Single-molecule imaging | Tracks tau oligomerization dynamics at nanometer resolution. |
| AI-driven aggregation prediction | Prioritizes compounds with anti-amyloid or anti-tau aggregation potential. |
| Microfluidic platforms | Monitors Aβ oligomerization kinetics under physiological shear stress. |
| High-resolution MS | Identifies low-abundance Aβ isoforms and post-translational modifications. |
Biochemical assays are the cornerstone of targeted Alzheimer's drug discovery. At Ace Therapeutics, we combine technical rigor with deep disease insight to help you unravel molecular mechanisms, optimize lead candidates, and de-risk your preclinical pipeline. Contact us today to discuss how our services can accelerate your research.
What sample types do you accept for Aβ aggregation assays
We analyze synthetic peptides, cell lysates, CSF, and brain homogenates. Minimum sample requirements are 10 µL for CSF or 50 µg protein for tissue lysates.
Can you differentiate Aβ oligomers from fibrils
Yes. Our FRET-based assays quantify oligomers, while Thioflavin T detects β-sheet-rich fibrils. TEM imaging is available for morphological validation.
How do you ensure assay reproducibility
We use standardized reference materials and include triplicate wells in all plate-based assays. Batch-to-batch CVs are maintained below 15%.
Do you support kinase inhibitor screening beyond GSK-3β
Yes. We offer CDK5, MARK4, and DYRK1A kinase assays. Custom kinase panels can be developed upon request.
What turnaround time can I expect for HTS projects
High-throughput screens (1,000+ compounds) typically take 4–6 weeks, including data analysis and reporting.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.